Arzerra (ofatumumab)

pCPA File Number: 20803
Negotiation Status:
Negotiations were not pursued
Indication(s):
Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Sponsor/Manufacturer:
GlaxoSmithKline
CADTH Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded: